Tempus ECG-AF vs Study Watch with Irregular Pulse Monitor
AI Verdict
Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if you need an AI-powered software solution to analyze existing 12-lead ECG recordings from patients aged 65 or older to identify those at increased risk of developing new-onset atrial fibrillation within the next 12 months. This tool is ideal for integrating into a healthcare facility's systems to proactively screen and route at-risk seniors for further diagnostic evaluation, leveraging existing ECG infrastructure.
View Tempus ECG-AF →Choose Study Watch with Irregular Pulse Monitor if…
Choose Verily Study Watch with Irregular Pulse Monitor if you require a prescription-only wearable device for continuous, long-term single-channel ECG rhythm monitoring and irregular pulse detection in adult patients (22+), particularly within clinical research or professional healthcare settings. This device is best suited for ongoing data capture and notification of potential atrial fibrillation, bridging the gap between invasive monitoring and consumer wearables for AFib detection and burden assessment.
View Study Watch with Irregular Pulse Monitor →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-AF | Study Watch with Irregular Pulse Monitor |
|---|---|---|
| Pricing | Contact vendor | Contact for pricing |
| Deployment | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. | Device-based (wrist-worn watch) |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Yes AI-estimated | True AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Study Watch with Irregular Pulse MonitorTool B, the Verily Study Watch, is a wrist-worn device designed for ease of use, with an intuitive interface and configurable firmware. It has been noted for its high patient usage in clinical trials and ease of explanation by physicians. Tool A, Tempus ECG-AF, is a software solution integrated into existing healthcare facility systems, which, while streamlining workflows for providers, doesn't offer the same direct patient-facing usability as a wearable device.
Clinical Value
TieBoth tools offer significant clinical value by aiding in the early detection of atrial fibrillation. Tempus ECG-AF analyzes 12-lead ECGs to predict AF risk within 12 months for patients 65+, with published multi-site validation studies supporting its FDA clearance. Verily Study Watch provides continuous single-channel ECG recording and irregular pulse monitoring for adults 22+, with clinical performance testing demonstrating high sensitivity and specificity for irregular pulse detection.
Pricing & Value
Tempus ECG-AFTempus ECG-AF has a clear advantage in pricing transparency and reimbursement, with established CPT codes (0764T and 0765T) and a Medicare reimbursement rate of $128.90 effective January 1, 2025. Tempus also offers a self-pay price of $295 and a financial assistance program. In contrast, Verily Study Watch requires contacting the vendor for pricing details, making its cost and value proposition less transparent for potential users.
Enterprise Readiness
Tempus ECG-AFTempus ECG-AF is designed as a software solution integrated into existing healthcare facility systems and EHRs, indicating a strong focus on enterprise deployment and workflow integration. Tempus also highlights its AI-enabled care platform, Tempus Next, which supports innovation across oncology and cardiology and is utilized by approximately 150 hospitals nationwide. While Verily's Study Watch is intended for professional healthcare settings and clinical research, its device-based deployment may present different integration challenges compared to Tempus's software-centric approach.
Innovation
Tempus ECG-AFTempus AI demonstrates broader and more rapid innovation in the AI healthcare space, with 37 AI-driven solutions released in the last 6 months alone, focusing on data science, automation, and image analysis. Tempus is actively embedding generative AI assistants and multimodal AI into EHRs and drug development workflows. While Verily is also innovative, particularly in wearables and digital biomarkers, Tempus's extensive portfolio of AI solutions and strategic collaborations across various disease areas suggest a more expansive and rapidly evolving innovation strategy.
Support & Docs
Tempus ECG-AFTempus provides clear contact information for customer service via phone and email, with a dedicated team available during business hours. They also offer comprehensive FAQs and policy documents covering billing, insurance, and financial assistance. While Verily's documentation and support details are not as readily available in the provided information or search results, Tempus's explicit communication channels and resources indicate a more transparent and accessible support structure.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-AF | Study Watch with Irregular Pulse Monitor |
|---|---|---|
| Tool Name | Tempus ECG-AF | Study Watch with Irregular Pulse Monitor |
| Company | Tempus AI, Inc. | Verily Life Sciences |
| Description | FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. | FDA-cleared, prescription-only wearable device designed for adult patients (22+) to monitor and record single-channel ECG rhythms and detect irregular pulses indicative of atrial fibrillation, primarily for use in clinical research and professional healthcare settings. |
| Target Patient Age | 65 years or older | 22+ |
| ECG Type | 12-lead ECG | Single-channel ECG |
| Key Detection Capability | Detects signs associated with new onset Atrial Fibrillation (AF) within 12 months | Irregular pulse monitoring and notification (e.g., for Atrial Fibrillation) |
| CMS Reimbursement | Available (CPT 0764T and CPT 0765T to APC 5734, Medicare rate of $128.90, effective January 1, 2025). | Not specified |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-AF and Study Watch with Irregular Pulse Monitor.
Frequently Asked Questions
More Comparisons
More matchups featuring Tempus ECG-AF or Study Watch with Irregular Pulse Monitor
Backers
Who funded each tool's parent company.